Participants 39 119 6
previously treated patients with refractory advanced non-small-cell lung cancer:
Participants 295 446 6
the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer.
Participants 455 658 8
1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care
Participants 942 996 5
1129 patients were assigned gefitinib and 563 placebo.
Participants 1236 1268 4
812 patients with adenocarcinoma
Participants 1440 1460 3
never-smokers (n=375
Participants 1528 1559 3
patients of Asian origin (n=342
Participants 1903 1971 3
evidence of benefit among never-smokers and patients of Asian origin
